WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced a new post hoc sub-analysis of key secondary endpoint data from the OASIS-1 and OASIS-2 pivotal trials for Lynkuet® (elinzanetant) 60mg capsules at 2026 The Menopause Society (TMS) Annual Meeting. In this sub-analysis, data from one of the key secondary endpoints, Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b), was analyzed to further evaluate the effect of Lynkuet on sleep disturbance i